Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Glomerular disease

Predicting outcomes in idiopathic membranous nephropathy

Several immunosuppressive treatments have demonstrated their efficacy in idiopathic membranous nephropathy, but spontaneous remission does develop in more than 30% of patients. The availability of a validated biomarker that is easy to measure and able to accurately predict long-term outcomes would be very helpful for tailoring treatment of the disease to the individual.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Renal survival in patients with idiopathic membranous nephropathy with urinary β2-m excretion <0.5 μg per min and ≥0.5 μg per min.

References

  1. Fervenza, F. C., Sethi, S. & Specks, U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin. J. Am. Soc. Nephrol. 3, 905–919 (2008).

    Article  Google Scholar 

  2. van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.00670112.

  3. Polanco, N. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697–704 (2010).

    Article  CAS  Google Scholar 

  4. Cattran, D. C. et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 51, 901–907 (1997).

    Article  CAS  Google Scholar 

  5. Branten, A. J. et al. Urinary excretion of β2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J. Am. Soc. Nephrol. 16, 169–174 (2005).

    Article  CAS  Google Scholar 

  6. du Buf-Vereijken, P. W., Branten, A. J. & Wetzels, J. F. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46, 1012–1029 (2005).

    Article  CAS  Google Scholar 

  7. van den Brand, J. A., Hofstra, J. M. & Wetzels, J. F. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 2846–2853 (2011).

    Article  CAS  Google Scholar 

  8. Beck, L. H. Jr & Salant, D. J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 77, 765–770 (2010).

    Article  CAS  Google Scholar 

  9. Hofstra, J. M., Beck, L. H. Jr, Beck, D. M., Wetzels, J. F. & Salant, D. J. Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286–1291 (2011).

    Article  CAS  Google Scholar 

  10. Beck, L. H. Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543–1550 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manuel Praga.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Praga, M., Rojas-Rivera, J. Predicting outcomes in idiopathic membranous nephropathy. Nat Rev Nephrol 8, 496–498 (2012). https://doi.org/10.1038/nrneph.2012.161

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2012.161

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing